Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. 87-årig kvinde påkørt af flugtbilist og helbredt for højmalignt lymfom

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Posterior reversibel encefalopati efterbehandling af malignt lymfom

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cerebralt aspergillom hos patient med immundefekt og follikulært lymfom

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: High-dose chemotherapy prior to autologous stem cell transplantation (ASCT) leads to adverse effects including mucositis, neutropenia and bacteremia. To reduce the toxicity, we treated myeloma and lymphoma patients with peroral bismuth as an adjuvant to chemotherapy to convey cytoprotection in non-malignant cells.

METHODS: This trial was a prospective, randomised, double-blind, placebo-controlled pilot study of hematological inpatients (n = 50) receiving bismuth or placebo tablets, in order to identify any potential superiority of bismuth on toxicity from chemotherapy.

RESULTS: We show for the first time that bismuth significantly reduces grade 2 stomatitis, febrile neutropenia and infections caused by melphalan in multiple myeloma, where adverse effects also were significantly linked to gender. In lymphoma patients, bismuth significantly reduces diarrhoea relative to placebo. Also, lymphoma patients' adverse effects were linked to gender. For the first time, bismuth is demonstrated as a safe strategy against chemotherapy's toxicity without interfering with intentional anti-cancer efficiency. Also, we show how gender significantly influences various adverse effects and response to treatment in both multiple myeloma and malignant lymphomas.

CONCLUSION: These results may impact clinical prevention of chemotherapy's cytotoxicity in certain patient groups, and also, this study may direct further attention towards the impact of gender during the course and treatment outcome of malignant disorders.

TidsskriftSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Udgave nummer4
Sider (fra-til)1279-1289
StatusUdgivet - apr. 2017

ID: 49836528